RECRUITING Phase 2 ClinicalTrials.gov

Safety and Tolerability of IDO-1 Inhibition in the Prevention of EBV-related Pathology in EBV Negative Kidney Transplant Recipients Receiving an Organ From EBV Positive Donors

Sponsor: University Hospital, Basel, Switzerland • ClinicalTrials.gov ID: NCT07368153

Registry updated: 2026-08-25

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

This clinical study will evaluate the safety and tolerability of an IDO-1 inhibitor in patients receiving a kidney transplant. The study includes individuals who have not previously been infected with Epstein-Barr virus (EBV) and who receive a kidney from a donor with prior EBV infection. Participants will receive the IDO-1 inhibitor or placebo in addition to standard medical care and will be monitored for side effects and other safety-related outcomes throughout the study.

Interventions

indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor (Drug)
Study treatment will be initiated one day prior to kidney transplantation or, for recipients of cadaveric donor organs, on the day of transplantation, and will be administered at a dose of 200 mg once daily for a total duration of 28 days, followed by a safety follow-up phase.
placebo (Drug)
A matching placebo will be administered once daily, initiated one day prior to kidney transplantation or, for recipients of cadaveric donor organs, on the day of transplantation, for a total duration of 28 days, followed by a safety follow-up phase.

Eligibility criteria

Inclusion Criteria: 1. Willing and able to provide informed consent 2. Male or female aged ≥18 years 3. EBV seronegative at the time of renal transplant 4. If women of child-bearing potential (WOCBP), participants must have a negative serum pregnancy test at screening and inclusion, and must be willing to use a highly effective method of birth control for the duration of the study. Acceptable methods of contraception: 1. Hormonal contraception associated with inhibition of ovulation 2. Intrauterine device (IUD) 3. Intrauterine hormone-releasing system (IUS) 4. Bilateral tubal occlusion 5. Vasectomised partner 6. Condom with spermicide 7. Sexual abstinence, in line with the preferred and usual lifestyle of the participant. Periodic abstinence (such as calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 5. If male, participants must be prepared to use reliable barrier method contraception and a second method such as spermicide for the duration of the study unless surgically sterile. Exclusion Criteria: 1. EBV seropositivity at the time of transplant 2. Participants with any form of cancer within the last 12 months, or patients continuing to receive chemo or immunotherapy within the last 12 months. 3. Participants with a history of PTLD 4. Other active systemic infections requiring treatment prior to and at the time of baseline. Prophylactic agents are permitted. 5. CYP3A4 and CYP2C28 Inhibitors and Inducers (List may be found in Appendix 1) 6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 x ULN 7. Any condition for which, in the opinion of the investigator, the treatment or participation in the study may pose a health risk to the participant 8. Planned or active participation in any other study with an investigational medicinal product (IMP). 9. Have taken an IMP within the last 3 months. 10. Unwilling or unable to provide fully informed consent. 11. Unwilling or unable to comply with study procedures.

Conditions

EBV Infections Kidney Transplant

Locations

University Hospital Bern — Bern, Canton of Bern, Switzerland
University Hospital Zurich — Zurich, Canton of Zurich, Switzerland
Centre hospitalier universitaire vaudois (CHUV) — Lausanne, Lausanne, Switzerland
University Hospital Basel — Basel, Switzerland

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment